Literature DB >> 6837832

A systemic lymphoproliferative disorder with morphologic features of Castleman's disease. Pathological findings in 15 patients.

G Frizzera, P M Banks, G Massarelli, J Rosai.   

Abstract

This report describes the nodal and extranodal lesions observed in 15 patients with a generalized disorder that had been histologically diagnosed as Castleman's disease. The disorder was characterized by severe constitutional symptoms, constant involvement of multiple peripheral lymph nodes, and frequent hepatosplenomegaly, in association with clinical and laboratory features reminiscent of a "collagen disease." The clinical course was chronic, with remissions and exacerbations in seven patients, and aggressive and fatal in eight. The material examined included multiple lymph node biopsies, four surgical specimens of spleen, one open lung biopsy, and material from four autopsies. The diagnostic morphological findings were observed in the nodes and were represented by the following histologic triad: diffuse marked plasmacytosis, from the medulla to the subcapsular areas; prominence of the germinal centers; and good preservation of the architecture. One variant of this basic pattern featured abundant immunoblasts and blood vessels. The process appears to be a systemic reactive proliferation of B-lymphocytes, perhaps resulting from faulty immune regulation. Morphologic similarities indicate a relationship between this multicentric disorder and Castleman's disease of plasmacellular type. However, there are distinct differences between them in clinical presentation and evolution, and, consequently, in therapeutic approach.

Entities:  

Mesh:

Year:  1983        PMID: 6837832     DOI: 10.1097/00000478-198304000-00001

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  53 in total

Review 1.  Portal hypertension and refractory ascites associated with multicentric Castleman's disease.

Authors:  M Abarca; R J Andrade; A García-Arjona; J L Escolar; A Blanes; J M García-Hirschfeld; P González-Santos
Journal:  Dig Dis Sci       Date:  2000-04       Impact factor: 3.199

2.  Giant lymph node hyperplasia of the mediastinum (Castleman's disease).

Authors:  M A Bhatti; J W Ferrante; I Gielchinsky; J C Norman
Journal:  Tex Heart Inst J       Date:  1984-12

3.  Giant lymph node hyperplasia (Castleman's disease): a clinical study of eight patients.

Authors:  Y Baruch; Y Ben-Arie; H Kerner; M Lorber; L A Best; R Gershoni-Baruch
Journal:  Postgrad Med J       Date:  1991-04       Impact factor: 2.401

4.  Multicentric Castleman's disease and HIV.

Authors:  John R Krause; Sara D Robinson; Estil A Vance
Journal:  Proc (Bayl Univ Med Cent)       Date:  2014-01

5.  Pathohistological and immunohistochemical studies on Castleman's disease of the lymph node.

Authors:  K Nagai; I Sato; N Shimoyama
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1986

6.  Castleman's disease of the left parotid gland: a case report.

Authors:  Zhenfei Guo; Chang Liu; Jing Sun; Linggong Zeng; Kai Zhang
Journal:  Int J Clin Exp Pathol       Date:  2021-04-15

Review 7.  Multicentric Castleman disease: Where are we now?

Authors:  Hao-Wei Wang; Stefania Pittaluga; Elaine S Jaffe
Journal:  Semin Diagn Pathol       Date:  2016-05-16       Impact factor: 3.464

8.  Multicentric Castleman's disease in a patient with primary Sjögren's syndrome.

Authors:  A Tavoni; C Vitali; P Baglioni; R Gerli; G Marchetti; O Di Munno; S Bombardieri
Journal:  Rheumatol Int       Date:  1993       Impact factor: 2.631

9.  Meningeal Castleman's disease with multifocal involvement: a case report and review of literature.

Authors:  Santiago Coca; Isabel Salas; Roberto Martínez; Miguel Angel Saez; Jesús Vaquero
Journal:  J Neurooncol       Date:  2008-01-18       Impact factor: 4.130

10.  A retrospective study of unicentric and multicentric Castleman's disease: a report of 52 patients.

Authors:  Bo Ye; Shu-Geng Gao; Wang Li; Long-Hai Yang; Shou-Hua Zhao; Ke Ma; Xiao-Lei Zhu; Xiang-Yang Liu; Ke-Ling Sun
Journal:  Med Oncol       Date:  2009-11-24       Impact factor: 3.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.